Abstract. The mobile phase additive (DMSO) has been described as a useful tool to enhance electrospray ionization (ESI) of peptides and proteins. So far, this technique has mainly been used in proteomic/peptide research, and its applicability in a routine clinical laboratory setting (i.e., doping control analysis) has not been described yet. This work provides a simple, easy to implement screening method for the detection of doping relevant small peptides (GHRPs, GnRHs, GHS, and vasopressin-analogues) with molecular weight less than 2 kDa applying DMSO in the mobile phase. The gain in sensitivity was sufficient to inject the urine samples after a 2-fold dilution step omitting a time consuming sample preparation. The employed analytical procedure was validated for the qualitative determination of 36 compounds, including 13 metabolites. The detection limits (LODs) ranged between 50 and 1000 pg/mL and were compliant with the 2 ng/mL minimum detection level required by the World Anti-Doping Agency (WADA) for all the target peptides. To demonstrate the feasibility of the work, urine samples obtained from patients who have been treated with desmopressin or leuprolide and urine samples that have been declared as adverse analytical findings were analyzed.
Introduction

O
ver the past few years, peptides have gained a markedly relevant role in pharmaceutical research and development [1] . Even though these new drugs are designed for specific therapeutic indications, some of them can be used to improve performance in sports. Consequently, several of them are included in the prohibited list published by WADA [2] . Within this class of peptide drugs, there is a group of peptides called Bsmall peptides.^These peptides have a molecular weight of less than 2000 Da. Their structure consists of short chains of amino acids (AAs) linked together by peptide bonds as base units. In contrast to some bigger peptides, the naturally occurring amino acids are not the only building blocks, an entire range of strategies based on chemical modifications (including synthetic AAs) are used to prolong their half-life [3] .
These small peptides cover growth hormone releasing peptides (GHRPs), gonadotropin releasing hormones (GnRHs), vasopressin analogues, and agonists of growth hormone secretagogue receptors (GHSRs). It has been reported that GHRPs can boost testosterone levels by stimulating the release of growth hormone [4] , GnHR agonists can alter the production of gonadotropin-releasing hormone [5] , and vasopressin and its synthetic analogue desmopressin can regulate urine production and thus can be used as a masking agent [6] . The thymosin beta-4 analogue TB-500 might help in faster recovery of muscle fibers and cells [7, 8] . Taking into account the potential benefits, these compounds are being used by athletes, and methods to detect them should be developed.
Without doubt, sophisticated chromatographic techniques coupled with mass spectrometry currently offer the most sensitive analytical platform to detect peptides at low concentrations [9] . Also in the field of anti-doping analysis, this technique has become the gold standard for the analysis of peptide drugs [10] . Hence, several comprehensive LC-MS detection methods have been described for the detection of small peptides in human urine [11] [12] [13] [14] [15] [16] and in equine urine [7, 17, 18] .
As a sample clean-up, all of them use a solid phase extraction (SPE) technology. Indeed, the polar nature of the peptides does not allow them to be extracted by liquid-liquid extraction and SPE is a popular technique for peptide drugs [19] .
Incorporating a sample preparation is often based upon compromises to be able to extract as many compounds, each with a sufficient recovery and in line with required sensitivity. For example, Mazzarino et al. describes a laborious SPE optimization procedure, coming to the conclusion that two types of elution mixtures are necessary for the simultaneous extraction of analytes with different properties [16] . Such off-line sample preparations are time-consuming, expensive, in cartridges, and prone to increase the likelihood of human error as well. These extraction issues were avoided by Thomas et al. in 2016 using a two-dimensional liquid chromatographic system coupled with an ion mobility mass spectrometer [14] . The disadvantage of such a system is the need for a double pump, which increases instrument and maintenance costs. Another promising approach is using a simple dilution as sample preparation (dilute-and-shoot) and subsequent injection in a conventional LC-MS system. Such an approach has been reviewed before [20] . However, due to the absence of a preconcentration step, the sensitivity of a dilute-and-shoot LC-MS method relies for a major part on the ionization of the targeted compounds [20] . Hence, a higher ionization efficiency has the potential to overcome sensitivity issues and consequently provide desired detection limits. Recently, an approach was presented to improve ionization efficiency of small peptides by Hahne et al. [21] . They proposed that the addition of low percentages of DMSO to the mobile phase enables the detection of peptides with poor ionization properties. Therefore, the aim of this work was to investigate the sensitivity of a dilute-and-shoot LC-MS method for small peptides using DMSO as a mobile phase additive.
Experimental
Chemicals and Materials
[deamino Cys1, Val4, D-Arg8] Vasopressin was purchased from Sigma Aldrich (Bornem, Belgium). TB 500 and its metabolites were synthesized in-house [8] . All the other peptides were obtained from the Australian Sports Drug Testing Laboratory (Sydney, Australia) and were synthesized by Auspep (Tullamarine, Australia). Bovine insulin was purchased from Sigma Aldrich (Bornem, Belgium). LC-MS grade acetonitrile (ACN) and water were obtained from J.T. Baker (Deventer, The Netherlands), formic acid (HCOOH) from Fisher Chemical (Madrid, Spain), acetic acid (HOAc) and dimethyl sulfoxide (DMSO) from Sigma Aldrich (Bornem, Belgium).
Stock and working solutions were prepared and stored in low binding microcentrifugal vials, type Eppendorf (Eppendorf, Hamburg, Germany). For performing the dilution steps, low retention pipette tips (Eppendorf) were used.
A mixture consisting of 90% water, 10% acetonitrile, and bovine insulin at the concentration of 1 μg/mL was prepared and used for the dilution of the samples. This solution is referred to as Bdilution mixture^in this study.
Instrumentation
The HPLC system consisted of an Accela LC (Thermo Scientific, Bremen, Germany) equipped with a degasser, Accela 1250 UPLC pump, an autosampler thermostated at 15°C and a thermostated (35°C) column compartment. An Agilent Zorbax RX C8 (2.1 × 150 mm) 5 μm particle size column was used for LC separation. Mobiles phases were A: H 2 O (containing 0.2% formic acid and 1% DMSO), and B: acetonitrile (containing 0.2% formic acid/ 1% DMSO). Gradient elution was as follows: 1% B, held for 4 min and increased to 35% in 20 min, then further increased to 90% in 2 min and held there for 3 min, decreased to 1% in 0.1 min and equilibrated for 3.9 min, giving a total runtime of 29 min. The flow rate was 0.3 mL/min.
The LC-system was coupled with a Q-Exactive benchtop quadrupole Orbitrap tandem mass spectrometer (Thermo Scientific, Bremen, Germany). The mass spectrometer was equipped with an electrospray ionization source. The parameters of the ion source were the following: spray voltage 4 kV; capillary temperature 250°C; heater 30°C; sheath gas 50; auxiliary gas 30; S-lens 100. The instrument was set to operate both in positive full scan and in positive multiplexed targeted ion monitoring. In full scan mode, the settings were the following: resolution 70,000; scan range 300-1075; agc target 1e6; maximum ion injection time 200 ms. In target sim mode, the settings were the following: resolution 70,000; scan range 300-1075; agc target 2e5; maximum ion injection time 200 ms; isolation window 2.5 m/z; msx 10. The mass extraction was done at 5 ppm. For the experiments to study charge state coalescence, the above described full scan monitoring was used with the change of scan range to 200-1500 m/z.
Preparation of Stock and Working Solutions
All peptide stock standard solutions were prepared at 0.1 mg/ mL using aqueous 2% acetic acid and were stored at -20°C. Working solutions (50, 25, 10 ng/mL) were prepared using the dilution mixture.
Excretion Study and Positive Urine Samples
As a proof of concept, five urine samples from patients who received desmopressin were obtained from the Department of Internal Medicine (Endocrinology) and Hematology of the Ghent University Hospital, with the approval of the Ethical Committee of the Ghent University (reference: B67020108809). Three patients received desmopressin intranasally (~10 mg/dose), two orally (200 mg).
Five urine samples from healthy male volunteers, 18 y and older, who were treated with leuprolide (1 mg subcutaneously injected) were analyzed. Ethics approval was granted by the Sydney South West Area Health Service Human Research Ethics Review Committee (Concord) consistent with National Health and Medical Research Council guidelines for ethical research involving humans and registered at the Australian and New Zealand Clinical Trial Registry (ACTRN12609000629235). Two samples that were declared positive for GHRP 6 and one for GHRP 2 were also analyzed. Samples were stored at -80°C awaiting analysis.
Sample Preparation
To 100 μL urine, 100 μL dilution mixture was added. All samples were mixed and centrifuged at 12,500 g-force for 5 min preceding the LC-HRMS analysis. Then, the microcentrifuge tubes were placed in the autosampler and 30 μL of the supernatant was injected. [deamino Cys1, Val 4, DArg8] AVP and 13C, 15N GHRP-2 (1-3) were used as internal standards and were added to the samples prior to the centrifugation step (2 ng/mL).
Preparation of Samples for Peptide Carrier Experiment
To investigate the effect of bovine insulin as a carrier peptide, two dilution series were prepared in the following manner: a 1 μg/mL mix of all peptides was prepared in duplicate, both containing ephedrine at the concentration of 100 μg/mL, but only to one of them bovine insulin was added at the concentration of 1 μg/mL. These solutions were further diluted to 250; 50; 10; 5; 2,5 ng/mL, making sure that the concentration of the carrier peptide was kept constantly at 1 μg/mL in one of the dilution series. At each dilution step, bovine insulin was added first to the vial. Finally to 100 μL of each solution 100 μL of an aqueous solution containing betamethasone was added and vortexed prior to the LC-MS analysis. Including ephedrine and betamethasone in the experiment guaranteed that the increased peak areas can only be attributed to the use of bovine insulin, not to low precision of injection volumes of the autosampler, or to human error committed during the dilution of the solutions.
Validation
Validation was carried out according to Eurachem Guidelines [22] . Therefore, 10 different blank urine samples were collected in a representative way covering a pH range of 5.08-6.24 and density of 1.012-1.031 g/cm 3 . Each urine sample was spiked at 2, 1, 0.5, 0.250, 0.125, 0.050 ng/mL to determine the LOD of the method, which was considered the lowest concentration at which the targeted analyte could be detected in all 10 urine samples with a signal-to-noise ratio greater than 3 and a retention time difference of less than 0.3 min to the reference.
To obtain concentrations of 2, 1, 0.5 ng/ml, 480, 490, 495 μL of blank urine was spiked from the 50 ng/mL working solution by the addition of 20, 10, 5 μL, respectively, to obtain peptide concentrations of 0.250, 0.125 ng/mL 495, 497, 5 of μL of blank urine was spiked from the 25 ng/mL working solution by adding 5, 2,5 μL, respectively, to obtain concentrations of 0.050 ng/mL 497,5 μL of blank urine was spiked from the 10 ng/mL working solution by the addition of 2.5 μL.
Retention time stability was assessed by comparing the retention time of the target analytes in matrix and in neat solutions without matrix.
Selectivity was tested during the validation procedure to probe for interfering peaks in the selected ion chromatograms at the expected retention times of the different peptides. For this reason, during the validation, 13 different mixtures of substances (in total 327 substances) from other doping classes were checked. Additionally, the 10 urine samples not spiked with the peptides were analyzed for interfering peaks. Matrix effects were expressed as the ratio of the average peak area of an analyte in 10 spiked blank urine samples (2 ng/mL) to the peak area of the same analyte in neat standard solution, multiplied by 100. A value greater than 100% indicates ionization enhancement and a value less than 100% indicates ionization suppression. Carryover was assessed by injecting blank samples (solvent used for dilution) after each urine sample during the validation process. The robustness of the method was demonstrated by analyzing several batches of routine urine samples that have been analyzed in our laboratory. Identical analytical columns but different in state of use were tested to check for increase of pressure.
Results and Discussion
Method Development
Since no preconcentration step is used in a dilute-and-shoot strategy, sensitivity relies on the ionization behavior of the target compounds, sensitivity of the mass spectrometer, and the stability of the compounds in solution. Therefore, these key elements were investigated during method development phase.
Effect of DMSO on the Electrospray Ionization
It has been revealed before that the nature of the chromatographic solvent can influence the process of the formation of electrospray droplets [23] [24] [25] . DMSO is one of the mobilephase additives that has been used in proteomic experiments by several research groups to enhance electrospray response [21, 26, 27] . One of the beneficial effects of including such solvents in the eluent is a remarkable gain in sensitivity that has been reported to be mainly caused by improved ionization efficiency, simply meaning that more ions enter the mass spectrometer. [21] To investigate this, a solution containing several of the peptide analytes at 2 ng/mL was injected twice using the same method but with the change of the addition of DMSO to both the aqueous and organic solvents. In Figure 1 , a comparison of the signal intensities of the most abundant charge states are presented.
On average signal intensities were 2-5 times higher with the DMSO-containing mobile phase. The improved sensitivity was significant but was less than the 10-fold increase observed elsewhere [21] . The highest increase was observed in the intensity of Lys-vasopressin (which could not be detected with conventional mobile phase compositions). This peptide has not been included in previously published methods, probably because of limited ionization capacities in absence of DMSO [14, 16] .
Besides the increased signal intensities, we observed that the use of DMSO also resulted in the coalescence of ion current into fewer charge states, more precisely in charge state reduction leading to more abundant lower charge states. Meyer and Komives explained the observed ESI MS signal improvement with this phenomenon, while Hahne et al. stated that it only accounts for merely 10%-20% of the gain in sensitivity and is caused by the high gas-phase basicity of DMSO (chargestripping) [21, 26] .
To study this phenomenon further, several peptides at a higher concentration (1μg/mL) were injected in the respective ion became the most abundant. For desmopressin (Figure 2b ), a reduction from +2 to +1 was noticed. A less prominent charge compression was observed for GHRP 6 (Figure 2c ). Charge state reduction could not be observed (or it was too low to be detected) for perforelin (Figure 2d ) when the comparison of the charge states was carried out. The highest detectable +3 charge state was the most abundant, irrespective of the mobile phase. This less outstanding effect could possibly be explained by the fact that perforelin has a structure with the charge (protons) to be more localized; therefore, it is less prone to be stripped in gas phase [21] . However; it has to be noted that as the focus of this work is on molecules with relatively short AA chain (5-10 AAs), our investigation has its limitations. The peptides of our interest are almost all present in +1 or +2 charge state. The infusion of analytes with longer AA chains would probably lead to a better and more comprehensive understanding of the observed compression of charge states but that was not the goal of the presented work.
Peptide-Stability, Storage Conditions
Urinary stability of small peptides has been investigated by several research groups. Mazzarino et al. report that fortified urine samples (5 ng/mL) are stable at least for 2 weeks at 4°C [16] . Timms et al. observed that after 7 d of storing the spiked human urine samples (50 ng/mL) at room temperature, GHRP levels between 38% and 100% were detected [17] . Thomas et al. found urine samples (20 ng/mL) stable for 3 wk at -20°C [14] . Ekatrine et al. recommend storage of urine samples at -80°C instead of -20°C since a drastic decrease was reported after 6 mo for GHRP 1 metabolites [12] . Besides this urinary stability, it has also been published that peptides can be lost from a solution due to absorption to recipient surfaces [28] . To avoid these losses and degradation effects, several precautions were taken. Because of the more basic properties of the target analytes, an aqueous solution containing 2% of acetic acid was used to dissolve the compounds. Addition of small amounts of organic solvents is also advised if hydrophobic residues approach 50% or more. Hence also 10% ACN was added to all solutions [29] .
Another phenomenon is that with increasing the dilution factor, unspecific losses can increase. To avoid this, a carrier peptide can be used [30] . Bovine insulin was arbitrarily chosen as carrier peptide since it does not interfere with the analysis. In Figure 3 , the effect of the carrier peptide is shown through the example of GHRP 5. It is clearly seen that decreased signal intensities might not be noticed when working with high concentrations; the issue becomes significant at low solute concentrations. While at 2,5 ng/mL the peak area is increased up to five times in the sample with bovine carrier, at 250 ng/mL the improvement is less significant (1, 20 times) . Maybe the aforementioned stability issues observed by the other research groups in urine can be due to this phenomenon.
It has to be noted that while the majority of the investigated analytes followed the same trend (2-to 5-fold peaks are increased at the lowest concentration and less or no improvement at higher concentrations), not all the of them could be recovered from the solution as good as the displayed GHRP 5 peptide. No improved peak area was observed in the case of ipamorelin (1-4) free acid, GHRP 2 (1-3) free acid, leuprolide (5-9), GHRP 1 (2-4) free acid, ipamorelin, leuprolide (1-3), terlipressin, Arg 8 vasopressine, hexarelin (1-3), Lys-vasopressin, TB-500 or its metabolites.
Method Validation
To guarantee that all doping laboratories can report the presence of prohibited substances, their metabolites, or markers in a uniform way, a minimum routine detection capability for testing methods has been established by WADA called the minimum required performance limit (MRPL) [2] . A developed method should be compliant to this MRPL.
The current MRPL level for small peptides is set at 2 ng/mL. The validated method presented in this paper shows good sensitivity and is capable of detecting 36 peptides including 12 metabolites at least at this MPRL. Table 1 summarizes the results of the validation. For 23 out of 36 compounds, the LODs were at least 10 times lower than the MRPL. These LODs were in the same order of magnitude as previous studies, but were obtained without solid phase extraction or with the aid of a 2D system [12, 14, 16] . It was observed that for some compounds, LODs of parent drug Peak areas that were generated using DMSO are indicated with red, peak areas that were generated without DMSO are indicated by blue and metabolites show a significant difference. While the LOD value for GHRP 6 parent ion is only 1000 pg/mL, that of the metabolites was found to be five or even 10 times better. The test for the assessment of the selectivity of the method showed no interfering peaks at the expected retention times of the analytes. Nevertheless, for confirmation purposes, a method with a higher degree of selectivity and using tandem mass spectrometry is recommended [31] .
The results of matrix effect test are listed in Table 1 . Great variation was observed across the 10 analyzed urine samples. For example, for AOD9604 the calculated values varied between 5% and 55%, giving an average of 28.6%.
This was also the observation of a previous research using direct injection [14] and was discussed by Panuwet et al., stating that urine concentration can vary drastically across individuals, depending on a variety of factors, including diet and hydration status [32] .
No carryover was observed in the blank samples injected after the urine samples. Despite the relatively large (30 μL) injection volume and only ½ dilution factor, no increase in pressure was noticed while running several batches of validation and routine urine samples. Possibly, non-dissolved particles are efficiently removed by the centrifugation step.
Evaluating the retention time criteria showed that 36 out of 38 compounds met the set requirement. For the early eluting TB-500 and one of its metabolite TB-500 (1-5), a retention time shift of more than 1 min in combination with deformed peak shape was observed. Timms et al. reported also peak deformation for small peptides due to the presence of the urine matrix [17] . The two substances were considered as notvalidated (NV). The detection of TB-500 was covered by Figure 4 . Extracted ion chromatograms of a blank urine sample (a), an adverse analytical finding (b), and a blank urine sample fortified at 2 ng/mL with the parent and metabolite peptides (c). The first row corresponds to GHRP-6, the second to GHRP-6 free acid, and the third to GHRP-6 (2-5) monitoring the TB-500 (1-3), which did not show such a problem. Besides, the latter substance showed also a better LOD.
Excretion Study Samples-Routine Samples
The suitability of the developed method for target analysis was proven by analyzing samples previously declared positive for the presence of small peptides and authentic samples from controlled administration studies. GHRP 2 and GHRP 6 parent ions could be detected in all corresponding excretion urine samples. Additionally GHRP-6 free acid and GHRP-6 (2-5) free acid metabolite for GHRP-6 were also present in the sample (Figure 4) . The identification and characterization of these metabolites have been studied before [13] . The presence of desmopressin and leuprolide was also confirmed in all corresponding excretion samples.
Conclusion
A simple comprehensive screening method for the detection of small peptides has been successfully developed and validated. The addition of DMSO reagent to the mobile phase enhances peptide ionization and allows applying a dilute-and-shoot strategy. The main benefits of the dilute-and-shoot strategy lie in time-and cost-saving by the omission of the sample preparation step. Taking into account the progressive increase of the sensitivity of recent mass spectrometers, even lower limits of detection are expected to be achievable in the near future using a dilute-and-shoot LC-MS strategy.
